Method and composition for targeted delivery of therapeutic agents
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichael R. McDevitt, Simone Alidori, Nima Akhavein, David A. Scheinberg
Life of this patent
Estimating the term…
Abstract
Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
Claims6
A method for preventing or reducing kidney injury in a subject, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for preventing or reducing kidney injury, the pharmaceutical composition comprising (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, wherein said siRNAs inhibit expression of MEP1B and p53 genes.
A method for reducing acute kidney injury in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition for reducing acute kidney injury, the pharmaceutical composition comprising:
- (1) siRNAs non-covalently conjugated to functionalized single wall carbon nanotubes (f-SWCNTs);
- and (2) a pharmaceutically acceptable carrier, wherein the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes.
Dependencies are inferred from the claim text.